SCHEMBL25237804

SCHEMBL25237804

COC(=O)c1ccc2c(c1)[nH]c(=O)c1c2ccn1C

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.62
CSNK2A1 P68400 1/20 0.56
KIF11 P52732 2/20 0.56
ALDH1A1 P00352 9/20 0.54
KMT2A Q03164 5/20 0.54
KDM4E B2RXH2 5/20 0.54
HPGD P15428 3/20 0.54
PKM P14618 2/20 0.54
HSD17B10 Q99714 2/20 0.54
GAA P10253 2/20 0.54
HTT P42858 2/20 0.54
GLA P06280 1/20 0.54
MEN1 O00255 3/20 0.49
POLB P06746 1/20 0.48
DYRK1A Q13627 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30413756 1.00 PARP1 (0.62) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL25234126 0.90 PARP1 (0.62) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL30414067 0.90 PARP1 (0.62) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL30414324 0.80 PARP1 (0.60) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL25239637 0.80 PARP1 (0.60) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL25293372 0.79 PARP1 (0.55) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL4725998 0.79 KIF11 (0.84) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL29708168 0.79 KIF11 (0.84) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL10134738 0.77 PARP1 (0.71) PARP1CSNK2A1KIF11ALDH1A1KMT2A
SCHEMBL25293367 0.77 PARP1 (1.00) PARP1CSNK2A1KIF11ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163022-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. 2025-05-22 US disclosed
WO-2024255697-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-12-19 WO disclosed
EP-4452963-A1 PARP1 INHIBITORS Synnovation Therapeutics, Inc. (US) 2024-10-30 EP disclosed
WO-2023122140-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163022-A1 PARP1 INHIBITORS PARP1, PARP11, PARP12 PARP1 1/4885CSNK2A1 1044/4885KIF11 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.